|Bid||73.69 x 100|
|Ask||83.09 x 100|
|Day's Range||78.10 - 79.44|
|52 Week Range||56.59 - 79.44|
|PE Ratio (TTM)||34.38|
|Dividend & Yield||1.32 (1.68%)|
|1y Target Est||N/A|
Share price of ResMed Inc. (RMD) scaled a new 52-week high of $79.22 on Jun 19, eventually closing a bit lower at $78.91.
A Relative Strength Rating upgrade for Resmed shows improving technical performance. Will it continue?
On June 7, 2017, Baxter International announced FDA approval and the commercial launch of its Clindamycin injection in saline.